People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

It appears an unintended side effect of the drug has now struck some of Britain's known suitmakers, who are fed up with ...

Research has found that GLP-1 receptors, found in medications like Wegovy and Monjaro, may offer health benefits beyond the ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

There's new evidence the class of drugs that includes Ozempic may have health benefits that go beyond diabetes treatment and weight loss. A major new study suggests these drugs could help with dozens ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

the main ingredient in the type 2 diabetes drug Ozempic and the weight loss drug Wegovy. Semaglutide remains on the FDA’s shortage list, and compounded versions of these drugs are permitted as ...

New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...